And right on cue last time, PEB announced capital raise on 15 Feb 2017.
This company is all too easy to read.
Sp now down 30% in 2 days from 46c, and down 45% from 59c since beginning of the year.
Printable View
Does page 13 imply that tests are now selling for circa $1000 each?
Content holder, have manged my holding correctly,
Very interested in PEB developing other markets (Singapore, Japan).
Its a pity guidelines are so slow. One only has to look at MDXhealth change of performance once their prostate product was included in the NCCN guidelines.
Some Insures are still requiring FDA approval before covering bc diagnostic tests. Not covering LDT sucks.
Some big lawsuits currently underway regarding Vets and exposure to chemicals and bad water. Hopefully VA can utilise Cxbladder to save some money and lives.
Wouldn't mind seeing Tolmar/PEB getting behind some of the 20k Qld firefighters in fighting bc. Changes in work cover laws now cover bc for those who have served over 15 years i believe.
Think ill look to add to my holding over the next few months and trade into positive announcements.
Good luck indeed, Carpenterjoe.
Always good to have a believer or many believers in a speculative stock like PEB.
Officially, doing 8,348 tests (including user programmes) - so just 54% less than what you thought they were doing in 2016.
You are right about abother CR - in fact, two so far and I suspect this one will be the last.
Fat lady is in front of the microphone.
Guess when PEB made this comment to NBR?
"Pacific Edge says that it has enough cash to continue operating at its cost base for another 15 months and hopes to secure sufficient sales to breakeven before that cash runs out".
It was Nov 2016.
https://www.nbr.co.nz/subscribe/197140
15 months to me means February 2018. But maybe, we are (as W69 often points out) we are in PEB time?
Feb 2017 - $8m capital raise.
Oct 2017 - $21m capital raise.
Not a company whose words you can trust - AT ALL!
Yup.
Latest update via the latest cap raise is that 2019 ACCRUED revenues are projected to be $27.9m - only 72.1% less than the $100m revenues, reaffirmed by the excitable excited David Darling with his trans-formative exciting inclinations towards user programs and the millions of exciting test opportunities in the US.